What are the recommended next steps for evaluating and managing a patient with severe fatigue and insomnia (difficulty falling asleep and staying asleep) who has not responded to trials of trazodone (which worsened fatigue), bupropion (Wellbutrin) (which caused excessive stimulation), and mirtazapine 15 mg nightly?

Recommended Next Steps for Refractory Insomnia with Fatigue

Given the failed trials of trazodone, bupropion, and mirtazapine 15mg, I recommend first increasing mirtazapine to 30-45mg nightly, and if this fails, switching to a Z-drug (zolpidem 10mg or eszopiclone 2-3mg) or dual orexin receptor antagonist (daridorexant 25mg or lemborexant 5-10mg) based on the predominant insomnia pattern.

Critical First Step: Rule Out Underlying Sleep Disorders

Before escalating pharmacotherapy, you must screen for:

• Obstructive sleep apnea (especially given severe fatigue despite sleep attempts)
• Restless legs syndrome (can cause both sleep initiation and maintenance problems)
• Medical contributors: thyroid dysfunction, anemia, chronic pain
• Psychiatric comorbidities: depression, anxiety disorders, PTSD (which may explain why standard hypnotics aren't working) 1

The severe fatigue despite attempted sleep suggests this may not be simple insomnia—consider polysomnography if clinical suspicion exists for sleep apnea.

Optimize Current Medication: Mirtazapine Dose Escalation

The patient is on a subtherapeutic dose. The FDA label specifies that if patients don't respond to 15mg, the dose should be increased up to 45mg daily, with changes made in 1-2 week intervals 2. At 15mg, mirtazapine primarily causes sedation through H1 antagonism, but at 30-45mg, it provides more robust noradrenergic and serotonergic effects that may better address both sleep and fatigue 2.

Recent meta-analysis data shows mirtazapine significantly increases total sleep time, slow-wave sleep percentage, and sleep efficiency while reducing wake after sleep onset 3. The patient may simply need adequate dosing.

Common pitfall: Clinicians often abandon mirtazapine at 15mg without proper dose titration. The therapeutic window for insomnia extends to 45mg 2.

If Mirtazapine Optimization Fails: Evidence-Based Alternatives

For Sleep Onset AND Maintenance Problems (Both Falling and Staying Asleep):

First-line pharmacologic options per AASM guidelines 4:

1. Eszopiclone 2-3mg: AASM suggests this for both sleep onset and maintenance insomnia. Recent network meta-analysis shows good efficacy with acceptable safety profile 5. However, avoid in older adults or those with respiratory/cognitive impairment 6.

2. Zolpidem 10mg: AASM-recommended for both sleep onset and maintenance 4. Network meta-analysis confirms efficacy after adjusting for age 5. Best used short-term (<6 weeks) or as-needed 6.

3. Lemborexant 5-10mg or Daridorexant 25mg (dual orexin receptor antagonists): These are particularly effective for sleep maintenance and show superior safety profiles compared to Z-drugs, with lower risk of respiratory depression 5. Daridorexant 25mg showed the strongest effect size for wake after sleep onset in recent meta-regression 5. These are preferred if the patient has any respiratory concerns or cognitive issues.

For Predominantly Sleep Maintenance Problems:

• Doxepin 3-6mg: AASM-recommended specifically for sleep maintenance 4. Network meta-analysis confirms significant reduction in wake after sleep onset 5.
• Suvorexant 10-20mg: AASM-suggested for sleep maintenance 4, though safety signals exist for nervous system disorders 5.

What NOT to Use:

The AASM explicitly recommends against trazodone for insomnia 4—which aligns with this patient's poor response. The guideline also recommends against diphenhydramine, melatonin (at standard 2mg doses), valerian, and tiagabine 4.

Address the Severe Fatigue Component

The persistent severe fatigue despite sleep attempts raises concern for:

1. Comorbid depression: The medication history (trying bupropion, mirtazapine) suggests this was considered. If depression is undertreated, insomnia won't resolve with hypnotics alone.

2. Sleep apnea masquerading as insomnia: Patients with undiagnosed OSA often present with fatigue and fragmented sleep that mimics insomnia 1.

3. Medication-induced fatigue: Trazodone worsened fatigue (expected), but mirtazapine at 15mg can cause excessive daytime sedation without therapeutic benefit 3.

Practical Treatment Algorithm:

Step 1: Screen for sleep apnea (STOP-BANG questionnaire, consider sleep study if high risk) and check TSH, CBC 1

Step 2: Increase mirtazapine to 30mg for 2 weeks, then 45mg if needed 2

Step 3: If no improvement after 4 weeks at adequate mirtazapine dose:

• If patient has respiratory issues, cognitive concerns, or is older: Switch to daridorexant 25mg or lemborexant 10mg 5
• If younger, healthy patient: Consider eszopiclone 3mg or zolpidem 10mg 4, 5
• If predominantly sleep maintenance problem: Consider doxepin 3-6mg 4

Step 4: Regardless of medication choice, strongly recommend cognitive behavioral therapy for insomnia (CBT-I) or digital CBT-I as first-line treatment—this should have been initiated before any medications 4, 1

Critical Safety Considerations:

• Screen for bipolar disorder before continuing/escalating antidepressants 2
• Monitor for agranulocytosis with mirtazapine (rare but serious: fever, sore throat, infection) 2
• Avoid benzodiazepines given abuse potential and lack of superiority 4
• Use Z-drugs at lowest effective dose for shortest duration (<6 weeks continuous use) 6
• DORAs (lemborexant, daridorexant) have better long-term safety profiles than Z-drugs 5

The combination of severe fatigue with refractory insomnia strongly suggests either inadequate dosing of current medication, undiagnosed sleep disorder, or undertreated psychiatric comorbidity—not simply treatment-resistant insomnia requiring ever-more medications.